Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

235
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
235
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

1.1K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
1.1K
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

47
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
47
Regulation of the Cardiovascular System01:27

Regulation of the Cardiovascular System

1.6K
The regulation of the cardiovascular system allows the body to adapt to various demands and maintain homeostasis.
The regulation of the cardiovascular system involves the autonomic nervous system (ANS), baroreceptors, and chemoreceptors, ensuring that heart rate and blood pressure are appropriately modulated in response to varying physiological demands.
The ANS comprises two main divisions: the sympathetic and parasympathetic nervous systems. The sympathetic nervous system enhances...
1.6K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

25
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
25
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

25
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
25

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Fully Automated Deep Learning Model for Quantifying Coronary Plaque at Coronary CT Angiography.

Radiology·2026
Same author

AI-enabled Quantitative High-Risk Plaque Attributes for Predicting Coronary Events in Nonculprit Vessels.

Radiology. Cardiothoracic imaging·2026
Same author

One-Year Outcomes of Novel Transcatheter Edge-to-Edge Mitral Repair System in Patients With Functional Mitral Regurgitation.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2025
Same author

De-escalating Dual Antiplatelet Therapy to Ticagrelor Monotherapy in Acute Coronary Syndrome : A Systematic Review and Individual Patient Data Meta-analysis of Randomized Clinical Trials.

Annals of internal medicine·2025
Same author

m<sup>6</sup>A Modification of Profilin-1 in Vascular Smooth Muscle Cells Drives Phenotype Switching and Neointimal Hyperplasia via Activation of the p-ANXA2/STAT3 Pathway.

Arteriosclerosis, thrombosis, and vascular biology·2024
Same author

Single-center experience with self-expanding transcatheter aortic valve system for symptomatic high-risk patients with severe aortic regurgitation: One-year outcomes.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2024

Related Experiment Video

Updated: Aug 27, 2025

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

732

DPP4 as a Potential Candidate in Cardiovascular Disease.

Si-Yu Chen1, Xiang-Quan Kong1,2, Ke-Fan Zhang3

  • 1Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, People's Republic of China.

Journal of Inflammation Research
|September 23, 2022
PubMed
Summary

Dipeptidyl peptidase-4 (DPP4) inhibitors, used for diabetes, show cardiovascular safety and potential therapeutic benefits. This review explores their role in managing cardiovascular diseases beyond blood glucose control.

Keywords:
DDP4 inhibitorDPP4GLP-1cardiovascular diseaseinflammation

More Related Videos

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

270
Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy
08:47

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy

Published on: December 7, 2017

9.8K

Related Experiment Videos

Last Updated: Aug 27, 2025

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

732
Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

270
Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy
08:47

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy

Published on: December 7, 2017

9.8K

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Cardiovascular disease (CVD) is a leading global health concern, with diabetes as a significant risk factor.
  • DPP4 inhibitors are a class of anti-diabetic medications.
  • Recent cardiovascular outcome trials have established the cardiovascular safety of DPP4 inhibitors.

Purpose of the Study:

  • To review recent advances in the understanding of DPP4 inhibitors' role in cardiovascular disease.
  • To discuss the potential of DPP4 inhibitors as a therapeutic option for cardiovascular conditions.

Main Methods:

  • Literature review of recent studies and clinical trials.
  • Analysis of the mechanisms by which DPP4 inhibitors affect cardiovascular risk factors and disease progression.

Main Results:

  • DPP4 inhibitors are cardiovascularly safe and demonstrate potential benefits in hypertension, calcified aortic valve disease, coronary atherosclerosis, and heart failure.
  • Beyond glycemic control, DPP4 inhibitors modulate cardiovascular risk factors.
  • DPP4 inhibitors exert direct effects on the development and progression of cardiovascular diseases through various pathways.

Conclusions:

  • DPP4 inhibitors offer a dual benefit in managing diabetes and cardiovascular health.
  • Their multifaceted mechanisms suggest a promising role in cardiovascular therapy.
  • Further research into DPP4 inhibitors for cardiovascular indications is warranted.